Wenzhou Yu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Wenzhou Yu has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
Li Li
National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases (NITFID), Center for National Immunization Program, Chinese Center for Disease Control and Prevention & Chinese Academy of Preventive Medicine, Beijing, China
5 shared publications- Jiakai Ye
National Immunization Program, Chinese Center for Disease Control and Prevention (Chinese Academy of Preventive Medicine), Beijing, China
4 shared publications Lei Cao
National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, Beijing, China
4 shared publicationsYifan Song
National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, Beijing, China
4 shared publicationsLingsheng Cao
National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
3 shared publicationsZhaonan Zhang
National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, Beijing, China
3 shared publications
Latest Publications
- Open Access
- 1 January 2026
- Published by Chinese Center for Disease Control and Prevention in China CDC Weekly
- Vol. 8 (17) , 507-512
The Current Status of Simultaneous Vaccination of Children Aged 0–3 Years — China, 2022–2024
What is already known about this topic? Simultaneous vaccination improves coverage and reduces clinic visits. In China, administering multiple vaccines during a single visit is widely practiced; studies have evaluated the safety and immunogenicity of specific vaccine combinations. However, systematic nationwide analyses remain limited. What is added by this report? During 2022–2024, 46.27% of vaccinations involved two vaccines administered simultaneously, 2.36% involved three, and 0.003% involved four or more. Most two-vaccine combinations included only National Immunization Program (NIP) vaccines, while combinations of three or more often included both NIP and non-NIP vaccines. What are the implications for public health practice? Real-world vaccination patterns provide evidence to inform research on multi-vaccine administration and combined vaccine development, supporting improvements in immunization service efficiency.
- 1 January 2026
- Published by Chinese Center for Disease Control and Prevention in China CDC Weekly
- Vol. 8 (17) , 507-512
Open AccessThe Current Status of Simultaneous Vaccination of Children Aged 0–3 Years — China, 2022–2024
What is already known about this topic? Simultaneous vaccination improves coverage and reduces clinic visits. In China, administering multiple vaccines during a single visit is widely practiced; studies have evaluated the safety and immunogenicity of specific vaccine combinations. However, systematic nationwide analyses remain limited. What is added by this report? During 2022–2024, 46.27% of vaccinations involved two vaccines administered simultaneously, 2.36% involved three, and 0.003% involved four or more. Most two-vaccine combinations included only National Immunization Program (NIP) vaccines, while combinations of three or more often included both NIP and non-NIP vaccines. What are the implications for public health practice? Real-world vaccination patterns provide evidence to inform research on multi-vaccine administration and combined vaccine development, supporting improvements in immunization service efficiency.
- Open Access
- 1 January 2024
- Published by Chinese Center for Disease Control and Prevention in China CDC Weekly
- Vol. 6 (19) , 418-423
Coverage of the Combined DTaP-IPV/Hib Vaccine Among Children Aged 2–18 Months — 9 PLADs, China, 2019–2021
What is already known on this topic? In China, there is limited data available on the use and coverage of the non-program, combined diphtheria, tetanus toxoid, acellular pertussis adsorbed, inactivated poliovirus and haemophilus influenzae type b (DTaP-IPV/Hib) pentavalent vaccine, and its role as a substitute for the separately administered standalone program vaccines. What is added by this report? We evaluated the use and coverage of the pentavalent vaccine in nine provincial-level administrative divisions (PLADs) spanning eastern, central, and western China from 2019 to 2021. Initial use and coverage were low, but demonstrated annual growth albeit with regional and urban-rural discrepancies. The pentavalent vaccine was increasingly substituted for standalone vaccines over the course of this period. What are the implications for public health practice? Parents in China are increasingly opting to replace the standard program vaccines with voluntarily purchased combination vaccines, particularly the pentavalent vaccine. The development of combination vaccines should thus be promoted in China, as it could enhance utilization and coverage rates, and decrease the economic burden.
- 1 January 2024
- Published by Chinese Center for Disease Control and Prevention in China CDC Weekly
- Vol. 6 (19) , 418-423
Open AccessCoverage of the Combined DTaP-IPV/Hib Vaccine Among Children Aged 2–18 Months — 9 PLADs, China, 2019–2021
What is already known on this topic? In China, there is limited data available on the use and coverage of the non-program, combined diphtheria, tetanus toxoid, acellular pertussis adsorbed, inactivated poliovirus and haemophilus influenzae type b (DTaP-IPV/Hib) pentavalent vaccine, and its role as a substitute for the separately administered standalone program vaccines. What is added by this report? We evaluated the use and coverage of the pentavalent vaccine in nine provincial-level administrative divisions (PLADs) spanning eastern, central, and western China from 2019 to 2021. Initial use and coverage were low, but demonstrated annual growth albeit with regional and urban-rural discrepancies. The pentavalent vaccine was increasingly substituted for standalone vaccines over the course of this period. What are the implications for public health practice? Parents in China are increasingly opting to replace the standard program vaccines with voluntarily purchased combination vaccines, particularly the pentavalent vaccine. The development of combination vaccines should thus be promoted in China, as it could enhance utilization and coverage rates, and decrease the economic burden.
- Open Access
- 1 January 2023
- Published by Chinese Center for Disease Control and Prevention in China CDC Weekly
- Vol. 5 (17) , 379-384
Coverage of 13-Valent Pneumococcal Conjugate Vaccine Among Children 0–15 Months of Age — 9 Provinces, China, 2019–2021
What is already known on this topic? Limited data exist regarding the coverage of the 13-valent pneumococcal conjugate vaccine (PCV13) in China. A lack of official statistics, coupled with an insufficient body of published literature, hinders the accurate depiction of the current situation. What is added by this report? This study investigated the utilization of PCV13 and estimated its coverage in nine provinces across eastern, central, and western China between 2019 and 2021. Despite an annual increase in PCV13 usage during this period, the overall coverage remained suboptimal. What are the implications for public health practice? Consideration should be given to incorporating vaccines into the Expanded Program of Immunization, reducing vaccine prices, and addressing the vaccination coverage gap between eastern and western regions when there is an adequate supply of PCV13, particularly with domestic vaccines.
- 1 January 2023
- Published by Chinese Center for Disease Control and Prevention in China CDC Weekly
- Vol. 5 (17) , 379-384
Open AccessCoverage of 13-Valent Pneumococcal Conjugate Vaccine Among Children 0–15 Months of Age — 9 Provinces, China, 2019–2021
What is already known on this topic? Limited data exist regarding the coverage of the 13-valent pneumococcal conjugate vaccine (PCV13) in China. A lack of official statistics, coupled with an insufficient body of published literature, hinders the accurate depiction of the current situation. What is added by this report? This study investigated the utilization of PCV13 and estimated its coverage in nine provinces across eastern, central, and western China between 2019 and 2021. Despite an annual increase in PCV13 usage during this period, the overall coverage remained suboptimal. What are the implications for public health practice? Consideration should be given to incorporating vaccines into the Expanded Program of Immunization, reducing vaccine prices, and addressing the vaccination coverage gap between eastern and western regions when there is an adequate supply of PCV13, particularly with domestic vaccines.
- Open Access
- 1 January 2020
- Published by Chinese Center for Disease Control and Prevention in China CDC Weekly
- Vol. 2 (50) , 968-974
Effectiveness of Catch-Up Vaccinations after COVID-19 Containment — China, 2020
- 1 January 2020
- Published by Chinese Center for Disease Control and Prevention in China CDC Weekly
- Vol. 2 (50) , 968-974
Open AccessEffectiveness of Catch-Up Vaccinations after COVID-19 Containment — China, 2020
- 27 February 2019
- Published by Springer Nature
- p. 131-141
Publicity and Communication of the Immunization Program
- 27 February 2019
- Published by Springer Nature
- p. 131-141
Publicity and Communication of the Immunization Program